← Back to headlines
Neurocrine Biosciences Raises INGREZZA Sales Guidance
Neurocrine Biosciences has increased its 2026 sales guidance for its drug INGREZZA to $2.825B-$2.875B, while also integrating VYKAT XR.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Meta, States Have Discussed Settling Teen Social Media Harm Case
15m ago
SpaceX plans to build the ‘biggest launch site on Earth’ for $100 billion in Louisiana - CNN
23m ago
Japan's Corporate Services Inflation Accelerates in July
29m ago
Multiple Company Executives Sell Shares in Various Transactions
1h ago